Sorrento Therapeutics, Inc. (SRNEQ)
OTCMKTS: SRNEQ · Delayed Price · USD
0.0300
+0.0010 (3.45%)
Apr 12, 2024, 3:52 PM EDT - Market closed
Sorrento Therapeutics Revenue
Sorrento Therapeutics had revenue of $64.27M in the twelve months ending June 30, 2023, with 16.89% growth year-over-year. Revenue in the quarter ending June 30, 2023 was $15.03M with 31.10% year-over-year growth. In the year 2022, Sorrento Therapeutics had annual revenue of $62.84M with 18.78% growth.
Revenue (ttm)
$64.27M
Revenue Growth
+16.89%
P/S Ratio
0.26
Revenue / Employee
$67,724
Employees
949
Market Cap
16.54M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 62.84M | 9.94M | 18.78% |
| Dec 31, 2021 | 52.90M | 12.92M | 32.31% |
| Dec 31, 2020 | 39.99M | 8.55M | 27.21% |
| Dec 31, 2019 | 31.43M | 10.24M | 48.31% |
| Dec 31, 2018 | 21.19M | -130.66M | -86.04% |
| Dec 31, 2017 | 151.86M | 143.70M | 1,762.81% |
| Dec 31, 2016 | 8.15M | 3.56M | 77.60% |
| Dec 31, 2015 | 4.59M | 765.00K | 20.00% |
| Dec 31, 2014 | 3.83M | 3.37M | 731.52% |
| Dec 31, 2013 | 460.00K | -124.00K | -21.23% |
| Dec 31, 2012 | 584.00K | 54.82K | 10.36% |
| Dec 31, 2011 | 529.18K | -153.38K | -22.47% |
| Dec 31, 2010 | 682.57K | - | - |
| Dec 31, 2009 | 0 | - | - |
| Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 371.62B |
| Johnson & Johnson | 85.16B |
| Merck & Co. | 60.12B |
| AbbVie | 54.32B |
| Novartis AG | 49.92B |
| AstraZeneca | 47.61B |
| Thermo Fisher | 42.86B |
| Abbott Laboratories | 40.11B |
SRNEQ News
- 2 months ago - Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. - Business Wire
- 7 months ago - Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company - PRNewsWire
- 8 months ago - Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 - GlobeNewsWire
- 8 months ago - Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients - GlobeNewsWire
- 9 months ago - Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid - PRNewsWire
- 9 months ago - Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders - GlobeNewsWire
- 10 months ago - Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders - PRNewsWire
- 10 months ago - Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study - GlobeNewsWire